<DOC>
	<DOCNO>NCT00410930</DOCNO>
	<brief_summary>To compare versus placebo efficacy safety recombinant Bet v1 , natural purify Bet v1 birch pollen licence extract use subcutaneous immunotherapy .</brief_summary>
	<brief_title>Efficacy Safety Subcutaneous Immunotherapy Birch Pollen Allergic Patients</brief_title>
	<detailed_description />
	<criteria>Patients age 1850 seasonal rhinoconjunctivitis least 2 year , and/or mild asthma range 1 2 GINA . Positive history birch pollen allergy ( clinical history , positive skin prick test , birch specific IgE , presence birch pollen ) Compliant patient Written consent . Perennial rhinoconjunctivitis and/or asthma due cosensitization : animal dander , mite , alternaria cladosporium Uncontrolled seasonal asthma : severe asthma permanent range 3 4 GINA . Patients treat betablockers continuous oral corticosteroid . Pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>Immunotherapy , major allergen , birch</keyword>
</DOC>